Martin Dewhurst was appointed Director of Turn Therapeutics Inc. As of November 14, 2026, Turn Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 7, 2026, naming 1 appointment (Form 8-K, January 7, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Turn Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Turn Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-07. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Turn Therapeutics Inc. files it.
Also on the record for Turn Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 26, 2026 | Form D, private offering | $1.65M sold | Form D page | Source |
| May 13, 2026 | Crowdfunding filing, Form C-TR | — | Crowdfunding | Source |
| April 6, 2026 | Stake report, Schedule 13G, by Bradley Burnam | 52.76% of the class | 5%+ stakes | Source |
| April 29, 2025 | Crowdfunding filing, Form C-AR | — | Crowdfunding | Source |
| March 25, 2025 | Crowdfunding filing, Form C-U | $15K target | Crowdfunding | Source |
| January 17, 2025 | Crowdfunding filing, Form C/A | $15K target | Crowdfunding | Source |
| December 18, 2024 | Crowdfunding filing, Form C/A | $15K target | Crowdfunding | Source |
| November 12, 2024 | Crowdfunding filing, Form C-U | $15K target | Crowdfunding | Source |
| October 22, 2024 | Crowdfunding filing, Form C | $15K target | Crowdfunding | Source |
| August 19, 2024 | Crowdfunding filing, Form C/A | $15K target | Crowdfunding | Source |
| July 15, 2024 | Crowdfunding filing, Form C/A | $15K target | Crowdfunding | Source |
Selling to them or working with them? See who runs Turn Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Turn Therapeutics Inc. and the records around it.
Turn Therapeutics Inc. elsewhere on the record
- Form D filing Aug 2026
- Crowdfunding filing May 2026
- Who owns it
Watch Turn Therapeutics Inc.
Get an email when Turn Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Turn Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Turn Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Turn Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-07 | In | Director | 8-K, 2026-01-07 |
Who leads Turn Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Martin Dewhurst, appointed (filed 2026-01-07).
New leaders reset buying decisions — get the Full Report on Turn Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Turn Therapeutics Inc., with the record behind each one.
Find candidates like Director at Turn Therapeutics Inc.Every change, in the filing's words
Appointed: Martin Dewhurst, Director
On January 7, 2026, the board of directors (the "Board") of Turn Therapeutics Inc. (the "Company") enlarged the Board from five to six members and appointed Martin Dewhurst to the Board, effective immediately.
- Mr. Dewhurst will serve as an independent Class III director until his term of office expires at the annual meeting of the Company's stockholders in 2028, or until his earlier death, resignation or removal.
- Mr. Dewhurst will serve as the chair of the compensation committee of the Board.
- Biographical information for Mr. Dewhurst is set forth below: Martin Dewhurst, age 62, has served as advisor to GHO Capital, a healthcare specialist private equity firm since July 2024.
- Mr. Dewhurst has been a senior advisor since April 2023 to PJT Partners, a global investment and M&A advisory bank.
- Mr. Dewhurst has also served as a senior advisor to LightRock, a growth capital fund, since April 2023.
- Mr. Dewhurst also holds various board positions including at Unilabs Ltd. (since September 2025), KOS AI (since June 2025), Cytovation ASA (since February 2025), Distalmotion (since April 2023) and MedGenome (April 2023 through January 2025).
- Prior to his various advisory and board roles, Mr. Dewhurst was a senior partner with McKinsey & Co., a leading management consulting firm where he served from 1992 through 2023 and co-led the firm's life sciences practice (2014 to 2021).
- Mr. Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD, where he graduated on the Dean's List.
Tools for this story
Each opens in a new tab, filled in for Turn Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
